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lecular interaction were registered while the temperature 
rose from –37 to 37  °  C. Individual macromolecular volume 
and molecular elasticity were determined for each patient. 
 Results: Clinical data revealed that 67% of UC and 79% of CD 
patients responded to infliximab therapy during the 3-month 
study period based on their respective clinical activity score. 
These results confirm that PIMS data predicted response to 
anti-TNF therapy with an accuracy of 96%.  Conclusion: PIMS 
stratified IBD patients into two groups, responders and non-
responders, which correlated with the clinical efficacy of an-
ti-TNF therapy. PIMS seems to be a powerful technology to 
adapt IBD treatment to the individual patient. Further stud-
ies with PIMS might enable to predict clinical response to 
biological treatment in IBD patients before the therapy is ini-
tiated.  © 2014 S. Karger AG, Basel 
 Introduction 
 Ulcerative colitis (UC) and Crohn’s disease (CD) are 
the most important entities of inflammatory bowel dis-
eases (IBD). Both diseases are characterized by acute/
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 Abstract 
 Background/Aims: Anti-tumor necrosis factor (TNF) anti-
bodies have clinical efficiency only in a subgroup of patients 
with inflammatory bowel diseases (IBD). Prediction of clini-
cal response is a critical clinical problem. Physiological inter-
molecular modification spectroscopy (PIMS) is a label-free 
technology performed in physiological conditions. PIMS en-
ables real-time monitoring of dynamic molecular resonance 
of entire proteins and macromolecules of an individual. The 
aim of this study was to explore the capacity of PIMS to dis-
criminate IBD patients regarding response to anti-TNF treat-
ment.  Methods: Protein extracts of peripheral blood mono-
nuclear cells (PBMC) from 30 outpatients diagnosed with ul-
cerative colitis (UC) or Crohn’s disease (CD) and treated with 
infliximab were subjected to PIMS analysis in a blinded trans-
versal study. Total protein from each patient’s PBMCs was 
challenged with infliximab. Dynamic changes in macromo-
 Dr. Pierre Eftekhari 
 ISIS 
 8 Allée Gaspard Monge 
 FR–67083 Strasbourg (France) 
 E-Mail p.eftekhari   @   inoviem.com 
 © 2014 S. Karger AG, Basel
0257–2753/14/0324–0446$39.50/0 
 www.karger.com/ddi 
 Predicting Response to Anti-TNF 
Therapy in IBD with PIMS 
Dig Dis 2014;32:446–454
DOI: 10.1159/000358151
447
chronic, destructive inflammation of the intestinal mu-
cosa. The annual incidence of IBD is 3–8.5/100,000 in 
European countries, and as many as 2.2 million individ-
uals in Europe and 1.4 million individuals in the United 
States suffer from IBD, with overall health care costs of 
more than EUR 2.5 and 1.2 billion, respectively  [1] . The 
immunopathological processes underlying CD have not 
been fully elucidated. To date, there is no causal treat-
ment because the pathogenesis of IBD is still unclear. 
New treatment options are based on the concept of a 
more targeted therapy. This is reflected by the therapeu-
tic efficacy of antibodies against tumor necrosis factor 
(TNF), which has been identified as one of the central 
proinflammatory cytokines in IBD immunopathogene-
sis. The chimeric monoclonal antibody infliximab and 
the human monoclonal antibody adalimumab have 
proven similar therapeutic efficacy in patients with IBD 
and have therefore both been approved for the induction 
and maintenance of remission in IBD patients in most 
parts of Europe  [2, 3] . However, about 50% of IBD pa-
tients do not respond to treatment with an anti-TNF an-
tibody and there are no reliable predictors for therapeu-
tic success  [4, 5] . Moreover, anti-TNF therapy may in-
duce severe side effects (opportunistic infections, allergic 
reactions, skin disorders and lupus-like autoimmunity) 
and result in a high economic burden, with costs equal-
ing nearly EUR 25,000/patient per year  [6] . Classifying 
IBD patients is crucial regarding therapeutic decisions. 
Therefore, there is an increasing interest in the discovery 
of new IBD biomarkers able to predict the future course 
of the disease and to improve the diagnosis and treat-
ment of IBD. These attempts have been restricted to ge-
nome identification for a long period. Recent technical 
advances, e.g. in the field of proteomics, subproteomics 
or metaboleomics, have gained marked interest, giving 
new hopes for biomarker identification in the field of 
IBD. Genome-wide analyses have led to the identifica-
tion of more than 163 different genes associated with 
IBD  [7, 8] . Proteomic and subproteomic analysis have 
additionally identified a large number of different pro-
teins dependent on the methodological approach, but 
currently these insights do not have any impact on clini-
cal practice in IBD.
 A very efficient way to improve treatment efficacy as 
well as deciphering CD and UC biomarkers is the use of 
therapeutics with proven clinical efficacy in these diseas-
es. Fair examples in this regard are already marketed bio-
logical drugs, such as anti-TNF antibodies. Thanks to 
this approach, we may be able to stratify patients with 
respect to treatment (individualized medicine). In turn, 
an individualized medicine based on drug efficiency cov-
ers two major aspects: one is to discriminate responders 
from nonresponders to anti-TNF therapy. Another as-
pect is the identification of biomarkers, which might be 
able to predict the clinical course of IBD or give indica-
tion of its possible progression. This consists of having 
indications on treatment efficiency, as early as possible, 
through precise information on the therapeutic index 
and identification of an adapted individualized treat-
ment.
 This methodological or technological interface should 
be straightforward, easy to handle, fast and able to reflect 
the global state of each patient with particular emphasis 
on IBD. Physiological intermolecular modulation spec-
troscopy (PIMS) has been developed to take these re-
quirements into account ( fig. 1 ).
 It is widely appreciated that almost all proteins and 
other biological macromolecules exist  in vivo, at least 
transiently, as components of structural and functional 
complexes. This transient interaction in simple compo-
nent solutions has been studied using a well-established 
Rayleigh light scattering (LS) method which reflects mo-
lecular oscillation  [9–14] . Protein association, protein 
unfolding, protein aggregation and cellular crowding 
are known to affect the normal function of cellular sys-
tems  [15–21] . Another physiochemical property of bio-
logical molecules is their absorption in the infrared 
range. Infrared absorption spectroscopy (IRAS) is a 
powerful biochemical analysis tool as it extracts detailed 
molecular structural information in a label-free fashion. 
Biological macromolecules can be studied using IRAS. It 
is also one of the classical methods to determine the 
structure of small molecules due to its sensitivity to 
chemical composition and molecule architecture. There-
fore, IRAS is a valuable tool for the investigation of pro-
tein structure, the molecular mechanism of protein reac-
tions and protein folding, unfolding and miswording 
 [22–31] . IRAS has a large application range from small 
soluble proteins to large membrane proteins, a high time 
resolution down to 1 μs with moderate effort and often 
a short measuring time, and a low amount of sample is 
required (typically 10–100 μg). Biological molecules do 
not exist alone, as they are always surrounded by water. 
The interaction and impact of water on proteins is re-
flected by the change in the proton spin of water mole-
cules and thus molecular resonance on the surface of 
proteins, which is deduced from nuclear magnetic reso-
nance relaxation  [32–36] .
 Based on these and the acquired knowledge on LS, the 
novel PIMS method has been developed. PIMS is a tech-
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nology based on dynamic molecular resonance of pro-
teins and macromolecules. PIMS is a label-free technol-
ogy that is able to study protein-protein and protein-sol-
vent interactions in multicomponent solutions. It 
provides individual real-time dynamic fingerprints of to-
tal physiological macromolecular assemblies in a tissue in 
the presence and absence of exogenous molecules (drug 
or drug candidates, peptides or proteins). It reflects the 
patient’s molecular capacity to respond to the drug and 
allows to discriminate different subpopulations of pa-
tients regarding response to a specific treatment. It dif-
ferentiates responders from nonresponders to a given 
treatment. 
 It takes into account a combination readout based on 
changes in the resonance of water molecules and macro-
molecular conformation. The latter can be used to predict 
treatment efficacy. PIMS provides very significant oppor-
tunities in the field of personalized medicine and bio-
markers.
 The aim of this study is to predict response to anti-
TNF treatment in IBD patients using the PIMS method 
on peripheral blood mononuclear cells (PBMC) of these 
patients before deblinding. The IBD patients included in 
this study were treated with an anti-TNF antibody and 
the response to the ongoing therapy was evaluated after a 
treatment period of 3 months.
 Patients and Methods 
 Patients 
 Venous blood was drawn from 30 consecutive outpatients (10 
females with a mean age of 40.8 ± 16.4 years and 20 males with a 
mean age of 41.5 ± 18.6 years) with an established diagnosis of UC 
(n = 18) or CD (n = 12) who had previously been treated with the 
anti-TNF antibody infliximab in the Medical Clinic 1 of the Uni-
versity of Erlangen. 
 Clinical disease activity was assessed in each patient using the 
Harvey-Bradshaw index (HBI) in CD and the total Mayo score 
(MS) in UC patients. Clinical disease activity scores were assessed 
prior to the initiation of the first infliximab treatment in all pa-
tients. All patients in this transversal study were reassessed regard-
ing their HBI after 12 weeks (±1) and the total MS after 12 weeks. 
Endoscopic examination, which contributed to the calculation of 
the total MS, was performed after 12 ± 3 weeks of therapy with in-
fliximab. Response to therapy in CD patients was defined as a 
3-point reduction in the HBI and remission as a HBI score <4 
points after 12 weeks of infliximab  [37] . In UC, response to thera-
py was defined as a reduction in the total Mayo score by at least 3 
points and 30% and remission was defined as a total MS <3 points 
after 12 weeks of infliximab therapy  [38] . Patients who responded 
or went into remission following infliximab according to the 
above-mentioned criteria were classified as ‘positive responders’ 
to therapy, while the other patients were characterized as ‘negative 
responders’ to therapy. Patients who remained in remission after 
infliximab therapy initiation were also classified as ‘positive re-
sponders’.
 All patients received infliximab therapy at weeks 0, 2 and 6 dur-
ing the time of the study. Infliximab doses given were 5 mg/kg per 
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 Fig. 1. Relation between the current state of 
the art and the important role of PIMS. 
PIMS is proposed to reconcile the data is-
sued from the -omics with clinical data and 
bridges the gap between -omics. 
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patient. Concomitant medication consisted of mesalazine, thiopu-
rines, corticosteroids or no other parallel therapy. The dose of con-
comitant medications was not increased during the study period. 
Patient characteristics (gender, age, treatment, response to treat-
ment and state of the disease) were blinded. Approval was granted 
by the competent Ethics Committee of the University of Erlangen. 
All patients gave written informed consent to participate in this 
study. 
 PBMC Isolation  
 From each patient, 20 ml of whole blood were collected in hep-
arin EDTA Vacutainer tubes. The blood was diluted with phos-
phate-buffered saline (PBS; ratio: 2/3, v/v). Thirty milliliters of 
whole blood/PBS mixture were gently placed over 20 ml of LSM 
1077 lymphocyte separation medium (PAA Laboratories, GmbH, 
Pasching, Austria) using two 50-ml conic tubes sufficient enough 
for PMBC separation of 40 ml of diluted blood. PBMC were sepa-
rated by centrifugation at 805  g for 20 min at 18   °   C. The isolated 
PBMC were washed 2 times in PBS at 652  g . Pelleted PBMC were 
frozen and stored at –80  °  C until use.
 Physiological Intermolecular Modification Spectroscopy 
 Total protein concentrations of each individual cellular
extract from the patients’ PBMC were determined using the 
BCA protein assay (Pierce, Thermo Scientific, Rockford, Ill., 
USA) according to the manufacturer’s recommendations. Pro-
tein (1 μg) was mixed with 10 –6  M infliximab. The blank con-
sisted only of 1 μg of total protein from the same patient’s PBMC 
with the same preparation using identical diffraction cells. PIMS 
were recorded accordingly when cellular extracts in physiologi-
cal conditions were frozen at –37   °   C. Macromolecular spectra 
were registered as the temperature within the sample rose from 
–37 to 37  °  C.
 PIMS Data Analysis 
 In order to get maximum information of the individual macro-
molecular spectra provided, the following distinct variables were 
studied:
 Variable 1 
 The calculated individual macromolecular volume (IMV) is 
defined as the total macromolecular spectral change from –37 to 
37   °   C due to macromolecular conformational changes in the ab-
sence and presence of a drug, expressed as a change in relative dif-
ferential diffraction as a function of wavelength and temperature. 
A small change in volume indicates a minor impact of the treat-
ment, whereas a major change underlines significant macromo-
lecular rearrangements and, therefore, a higher probability for a 
therapeutic effect.
 Variable 2 
 Molecular elasticity (ME) is defined as a change in relative 
differential diffraction for temperatures of –10 and –5   °   C as a 
function of wavelength. The ME variable is a fine-tuning but-
ton, allowing to calculate the impact of the drug or xenobiotic 
on ME ( fig. 2 ). The higher the intramolecular potential energy, 
the lower the degree of ME. It is calculated using the following 
formula: 
 where DMO is differential molecular oscillation and RDD is rela-
tive dynamic diffraction at –10 and –5  °  C.
 Patients with a ratio of ME higher than zero were considered 
as responders. A ratio equal to zero was considered as borderline.
 DMO is defined as the difference in molecular resonance as a 
function of time and surrounding environment in the presence of 
infliximab compared to the blank. 
 RDD depends on surrounding water molecules in the presence 
of infliximab compared to the blank. Any change induced by inf-
liximab in the patients’ protein assemblies will change water dif-
fraction as the temperature rises from –10 to –5  °  C.
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 Fig. 2. Ratio of RDD based on 2 patients’ ME from –10 to –5   °   C. 
 a ME for a responder to anti-TNFα therapy at –10   °   C does not 
change in the presence/absence of infliximab (red and black lines, 
respectively). At –5   °   C, ME is modified in the presence of infli-
ximab (gray line) compared to the blue line in the absence of infli-
ximab. b ME for a non-responding patient to anti-TNFα therapy 
at –10 and –5°C. There are no changes in presence and absence of 
infliximab (red and black lines, respectively; colors are shown in 
the online version only). 
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 Results 
 Clinical Response to Infliximab 
 In the group of patients with CD, 9 patients were ‘pos-
itive responders’ (75%) and 3 were ‘negative responders’ 
(25%) to the 12-week infliximab treatment ( table 1 ). In 
the group of patients with UC, 12 patients turned out to 
be ‘positive’ (67%) and 6 patients ‘negative responders’ 
(33%) to the 12-week infliximab treatment ( table 2 ). CD 
patients 4 and 9 and UC patients 2, 12 and 13 were in re-
mission when the first infliximab application took place 
and were still in remission when they were reassessed af-
ter 12 weeks ( table 1 ,  2 ). These patients were also classi-
fied as ‘positive responders’ to infliximab.
 Individual Macromolecular Volume 
 PIMS results plotted in three axes (DMO, RDD and 
temperature) revealed three different infliximab groups 
compared to the baseline ( fig. 3 ). One group showed in-
trinsically higher LS capacity, which was attenuated or 
abolished in the presence of infliximab (group A). A sec-
ond group showed low LS capacity, which was increased 
in the presence of infliximab (group B). The third group 
had either high or low intrinsic LS capacities and remained 
unchanged in the presence of infliximab (group C). 
 Molecular Elasticity 
 Infliximab changed ME with regard to altered molecular 
resonance and therefore the pattern of scattered light be-
tween –10 and –5   °   C. We identified two distinct groups. 
Among IBD patients, we characterized a responder group 
(n = 21) and a nonresponder group (n = 9). More precisely, 
PIMS prediction in regard to CD identified 10 responders 
(83%) and 2 nonresponders (17%). In UC, PIMS character-
ized 12 patients as responders (67%) and 6 patients as non-
responders (33%). These results are summarized in  table 3 .
 One patient was considered as borderline (ME = 0). 
The patient was considered as nonresponder as there 
were no differences between the IMV at baseline and in 
the presence of infliximab. The results are summarized in 
 table 3 . 
 Clinical responses confirmed PIMS prediction in 96%. 
In 1 of these patients, PIMS prediction was not in line 
with the clinical response to infliximab therapy; this pa-
tient with ME = 1 was considered as a nonresponder, but 
clinically response to anti-TNF therapy was noted ( fig. 4 ).
 Discussion 
 Anti-TNF antibodies have established themselves as a 
valuable treatment option in IBD patients and are widely 
used in daily clinical practice nowadays  [4] . However, 
about 50% of the patients do not respond to anti-TNF 
therapy  [39] and there are currently no reliable biomark-
ers that may allow the stratification of patients into re-
sponders or nonresponders to therapy prior to its initia-
tion. Finding a novel approach to establish predictive bio-
markers for therapeutic response is therefore an important 
Table 1.  Clinical data of the CD patients
Patient
No.
Sex Diagnosis HBI 
week 0
HBI 
week 12 ± 1
Clinical result
1 m CD 11 9 no response
2 f CD 4 7 no response
3 m CD 9 12 no response
4 m CD 3 2 remission
5 m CD 7 2 remission
6 f CD 11 5 response
7 m CD 4 1 remission
8 m CD 5 1 remission
9 f CD 1 2 remission
10 m CD 16 12 response
11 f CD 4 3 remission
12 m CD 6 3 remission
Table 2.  Clinical data of the UC patients
Patient
No.
Sex Diagnosis MS 
week 0
MS 
week 12 ± 3 
Clinical result
1 m UC 4 11 no response
2 f UC 2 0 remission
3 m UC 9 10 no response
4 m UC 6 2 remission
5 m UC 9 0 remission
6 m UC 4 6 no response
7 f UC 7 2 remission
8 m UC 8 5 response
9 m UC 4 2 remission
10 m UC 6 6 no response
11 m UC 7 2 remission
12 f UC 2 2 remission
13 f UC 2 1 remission
14 m UC 5 2 remission
15 f UC 3 3 no response
16 m UC 5 3 no response
17 m UC 4 1 remission
18 m UC 10 7 response
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Table 3.  PIMS results (blinded) of IBD patients’ response to anti-TNF therapy
Results Patients, % Responders, %  Nonresponders, %
IBD CD UC CD UC  CD UC
PIMS results (blinded) Total (n = 30) 100 (n = 12) 100 (n = 18) 83 (n = 10) 67 (n = 12) 17 (n = 2) 33 (n = 6)
Clinical results after deblinding 75 (n = 9) 67 (n = 12) 25 (n = 3) 33 (n = 6)
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clinical aim, as it is not only important for the patients’ 
well-being but would also avoid unnecessary side effects 
in patients with no or minor therapeutic benefit and 
would also reduce the expenses of the national health in-
stitute for individual health care.
 The pathophysiology of IBD, which may vary between 
patients, poses the first problem to find a reliable bio-
marker for therapeutic response to anti-TNF treatment. 
This is reflected by efforts that were not able to identify 
serological biomarkers which could be used as stand-
alone tools in clinics. Accordingly, conduct, analysis and 
interpretation of studies in IBD may be constrained to 
varying degrees by the prevalence of the disease at times. 
An individualized medicine with regard to identified pro-
teins based on comparative studies is almost impossible. 
 In our IBD group including CD and UC patients, the 
percentage of ‘positive responders’ was higher than al-
ready reported (75 and 67%, respectively). This might be 
explained by the transversal study setup were some pa-
tients were already in remission in both groups when in-
fliximab therapy was started. Since the clinical data of the 
patients were blinded when the PIMS experiments were 
performed, we still included these patients in our study 
and assessed if anti-TNF therapy was able to maintain re-
mission during the study time. We postulated that the 
maintenance of remission during the study period could 
be assessed as ‘positive response’ to infliximab. 
 Using an observation method that allows discrimina-
tion on the basis of morphological differences within a 
patient group with the same pathology would pave the 
way for further developments that would include the iso-
lation and identification of biomarkers. PIMS is an ex-
ploratory technology able to highlight characteristic mor-
phological protein assemblies within a tissue. The ob-
served effect of infliximab on the responders’ population 
could be explained by the fact that macromolecular inter-
actions were preserved due to physiological conditions. 
There was no addition of any anti-phosphatase or anti-
protease cocktails, nor were any denaturing or reducing 
agents used, which might have had an impact on sero-
logical biomarkers and could have influenced the results. 
Physiological osmolality and cellular ion composition 
were not altered. In fact, in responder groups, infliximab 
affects macromolecular assemblies. It changes thermody-
namic relations in and between macromolecular assem-
blies as well as those with intrinsic water molecules. This 
would change molecular enthalpies and therefore result 
in a defrosting pattern. We performed continuous sam-
pling from –37 to 37  °  C and changes were compared as a 
function of time and temperature. The temperature is a 
necessary component for two reasons: freezing amplifies 
the signal and its sensitivity, and therefore allows discrim-
ination between the patients. There are intraindividual 
differences in cellular composition and specific protein 
concentration which lead to different freezing times. Fur-
thermore, at –37   °   C some molecular resonance will at-
tenuate more than another (thanks to the quaternary 
structure of the proteins). The longer it takes to defrost, 
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the higher the molecular interaction which would there-
fore affect the pattern of scattered light  [21, 22] . If inflix-
imab has an impact on protein structure, their resonance 
will be changed in a frozen state. These changes are dy-
namic since temperature rises continuously. 
 PIMS gives precise morphological information on the 
patient’s total PBMC protein and macromolecules in the 
presence of infliximab. This is due to molecular resonance 
within and between molecules, which can be deduced 
thanks to the Schrödinger equation, where only two com-
ponents, space (x) and time (t), are considered. The prob-
ability of a molecule to move in space and meet another 
particle has been considered as one of the bases of quan-
tum physics and underlines nuclear magnetic resonance 
technology. Another well-established law in quantum 
physics is the infrared absorption known as Raman spec-
tra. The changes in molecular absorption spectra at 1–5 
μ M give precise information on molecule size and its rela-
tion to the surrounding environment  [28–32] . PIMS com-
bines molecular resonance and infrared spectra. The mo-
lecular resonance is mostly related to surrounding water 
molecules as their resonance is different on the surface of 
proteins, within the quaternary structure of the same pro-
tein or totally free from any contact with proteins  [33–36] . 
When a protein changes its conformation (infrared spec-
troscopy), it changes also the resonance of related water 
molecules and therefore their absorption spectra. 
 PIMS discriminated three different groups. We ob-
served differences at baseline among the patients. One 
reasonable explanation could be the ongoing anti-TNF 
therapy in most of the patients. This would have some 
impact on molecular resonance. We did not have any idea 
about the presence of anti-TNF antibodies or infliximab 
trough levels at the moment of blood sampling. In future 
studies, this should be completed by adapted immuno-
chemical assays both in sera and on PBMC.
 If infliximab interacts with the patient’s PBMC protein 
assembly and modifies the molecular resonance in such 
way that it initiates a cascade of reactions extending to 
surrounding proteins and changes the mean molecular 
resonance for all existing macromolecules in a given time, 
it would reflect its pharmacological activity in vivo (it 
mimics the cellular signalization cascade).
 Here, PIMS has shown to be a promising tool for the 
stratification of patients into responders and nonre-
sponders. We have chosen a transversal, small-size clini-
cal study in order to challenge the PIMS technology. It 
was important to see whether this technology was able to 
discriminate a specific pattern among the patients disre-
garding their gender, age, treatment and treatment dura-
tion. It was also important to challenge its robustness with 
respect to study size. We are currently running a longitu-
dinal study where these points are addressed in patients 
during follow-up. Further investigations are needed to 
see whether PIMS could be a reliable predictor of the ef-
ficacy of anti-TNF treatment. 
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